Coatue Management Reduces $20M in Natera, Inc. ($NTRA)

Coatue Management recently trimmed its stake in Natera, Inc. (NasdaqGS: NTRA) by 91,492 shares, according to its latest 13F filing with the SEC. This reduction represents a 3.47% decrease in Coatue's holdings, bringing their total to 2,541,842 shares valued at approximately $553.7 million as of the reporting period.

What Changed in Coatue Management's Natera Position

Coatue Management reduced its position in Natera from 2,633,334 shares to 2,541,842 shares, cutting 91,492 shares in total. This move represents a 3.47% decrease in their holdings, with the remaining shares valued at around $553.7 million.

Other Institutional Activity in Natera

JPMorgan Chase & Co boosted its holdings in Natera by 532,333 shares, ending with 13,386,667 shares worth about $2.50 billion. Price T Rowe Associates also increased its stake by 1,312,887 shares, resulting in a total of 12,184,876 shares valued at approximately $2.44 billion. Meanwhile, BlackRock, Inc. slightly reduced its position by 182,103 shares, now holding 10,677,338 shares valued at $2.14 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC added new positions of 6,008,496 and 5,644,695 shares, respectively, with values of $1.20 billion and $1.13 billion.

Natera, Inc. Stock Snapshot

Shares of Natera, Inc. (NasdaqGS: NTRA) traded near $217.86. The company has a market cap of $30.37 billion and a forward P/E ratio of -1017.71, indicating it is not currently profitable. Natera’s stock has a 52-week range between $131.81 and $256.36, with a 50-day moving average of $206.46 and a 200-day moving average of $205.21. The company shows a current ratio of 2.96 and a quick ratio of 2.70, with a debt-to-equity ratio of 13.53.

Recent Earnings

Natera reported revenue of $2.50 billion, growing by 38.8% year-over-year. However, the company is not profitable, with a net margin of -9.05% and a return on equity of -15.02%. The next earnings report is expected on May 7, 2026.

Insider Buying and Selling at Natera, Inc.

Recent insider transactions at Natera include Marcus Gail Boxer selling 11,000 shares at an average price of $217.21 on June 5, 2026, and also buying the same amount on the same day at a significantly lower price of $22.83. CEO Steven Leonard Chapman sold 41,124 shares at $221.03 on June 4, 2026, as part of a planned transaction. Roelof Botha and Solomon Moshkevich also sold shares on June 1, 2026.

Analysts Set New Price Targets

On June 12, 2026, RBC Capital reinstated Natera with a buy rating and a $275 price target. Goldman Sachs initiated coverage with a hold rating and a $245 target on June 5, 2026. Wolfe Research assumed coverage with a buy rating and a $260 target on June 2, 2026. The consensus among 20 analysts is a buy rating with a mean price target of $260.05.

About Natera, Inc.

Natera, Inc., headquartered in Austin, Texas, is a diagnostics company specializing in molecular testing services. The company offers a range of tests, including the Signatera blood test for cancer monitoring and the Panorama non-invasive prenatal test. With a focus on personalized medicine, Natera serves various healthcare providers and has partnerships for genetic testing development.

Bottom Line

Coatue Management's decision to trim its stake in Natera reflects a modest reduction in its investment in the diagnostics company. Investors often track such filings to gauge institutional sentiment, though they are backward-looking and may not reflect current positions. Natera continues to attract attention from analysts and institutional investors, highlighting its role in the healthcare diagnostics sector.